For five years, Teva’s stock tumbled amid a potent cocktail of serious and widespread legal allegations, declining company and industry-wide revenue and debt that creaked more heavily each passing year. Now, their CEO and some investors think they can see the light.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,